Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Mon Jan 12, 10:15AM CST

NEW HAVEN, Conn. , Jan. 12, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 13.14 (+10.23%)
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 PR Newswire - Wed Jan 7, 6:00AM CST

NEW HAVEN, Conn. , Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan...

BHVN : 13.14 (+10.23%)
New York Stock Exchange during sunrise by Deberarr via iStock
S&P Futures Muted in Thin Post-Christmas Trade Barchart - Fri Dec 26, 2025

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened...

NVDA : 186.23 (-0.44%)
BHVN : 13.14 (+10.23%)
INTC : 46.96 (-2.81%)
NEM : 114.12 (-0.08%)
MU : 362.75 (+7.76%)
LRCX : 222.96 (+2.52%)
NKE : 64.38 (-0.33%)
DVAX : 15.63 (+0.06%)
CPNG : 21.13 (-0.56%)
FCX : 58.71 (-2.08%)
ESH26 : 6,976.75s (-0.07%)
ON : 60.33 (+0.08%)
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder PR Newswire - Wed Dec 24, 2025

NEW HAVEN, Conn. , Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 13.14 (+10.23%)
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress PR Newswire - Thu Dec 11, 2025

LONDON and NEW HAVEN, Conn. , Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society...

BHVN : 13.14 (+10.23%)
Author
Biohaven Insiders Bet $33 Million on a Turnaround MarketBeat - Thu Nov 20, 2025

Biohaven's leadership made a massive multi-million dollar investment in their own stock, signaling deep confidence in the company's turnaround plan.

BHVN : 13.14 (+10.23%)
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M PR Newswire - Thu Nov 13, 2025

NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.  (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 13.14 (+10.23%)
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares PR Newswire - Wed Nov 12, 2025

NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.  (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 13.14 (+10.23%)
Biohaven Announces Proposed Public Offering of Common Shares PR Newswire - Tue Nov 11, 2025

NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing...

BHVN : 13.14 (+10.23%)
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments PR Newswire - Mon Nov 10, 2025

NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

BHVN : 13.14 (+10.23%)

Barchart Exclusives

As Apple Teams Up with Google on Siri AI Upgrades, Should You Buy AAPL Stock? Barchart - 8 minutes ago
Apple’s decision to tap Google’s Gemini AI to supercharge Siri is redefining its AI strategy. Is AAPL a buy now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot